S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
New CBOE “special perk” helps traders target income every weekend (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

National Research Stock Price, News & Analysis (NASDAQ:NRC)

$41.50
0.00 (0.00%)
(As of 12/5/2023 ET)
Compare
Today's Range
$41.41
$41.60
50-Day Range
$40.51
$46.39
52-Week Range
$36.61
$47.60
Volume
122,394 shs
Average Volume
37,763 shs
Market Capitalization
$1.02 billion
P/E Ratio
35.78
Dividend Yield
1.16%
Price Target
N/A

National Research MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.16mentions of National Research in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$117,651 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Business Services Sector

243rd out of 285 stocks

Commercial Physical Research Industry

10th out of 10 stocks


NRC stock logo

About National Research Stock (NASDAQ:NRC)

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, workforce engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

NRC Stock Price History

NRC Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
National Research (NASDAQ:NRC) Sees Unusually-High Trading Volume
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
See More Headlines
Receive NRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for National Research and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/22 Dividend
9/15/2023
Dividend Payable
9/22/2023
Last Earnings
11/07/2023
Today
12/05/2023
Ex-Dividend for 1/12 Dividend
12/28/2023
Fiscal Year End
12/31/2023
Dividend Payable
1/12/2024
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:NRC
Employees
491
Year Founded
1981

Profitability

Net Income
$31.80 million
Pretax Margin
25.53%

Debt

Sales & Book Value

Annual Sales
$151.57 million
Cash Flow
$1.51 per share
Book Value
$2.92 per share

Miscellaneous

Free Float
23,969,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
0.43

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael D. Hays (Age 68)
    Founder, CEO, President & Director
    Comp: $131.65k
  • Mr. Kevin R. Karas CPA (Age 65)
    Senior VP of Finance, CFO, Treasurer & Secretary
    Comp: $292.81k
  • Ms. Jona S. Raasch (Age 64)
    Chief Operating Officer
    Comp: $308.01k
  • Ms. Helen L. Hrdy (Age 58)
    Chief Growth Officer
    Comp: $291.31k
  • Mr. Jon Boumstein
    Chief Delivery Officer
  • Dr. Gregory Makoul M.S.
    Ph.D., Chief Transformation Officer
  • Linda Stacy
    Vice President of Finance
  • Megan Charko
    Senior Manager of Content Marketing














NRC Stock Analysis - Frequently Asked Questions

How have NRC shares performed in 2023?

National Research's stock was trading at $37.30 on January 1st, 2023. Since then, NRC stock has increased by 11.3% and is now trading at $41.50.
View the best growth stocks for 2023 here
.

Are investors shorting National Research?

National Research saw a increase in short interest in November. As of November 15th, there was short interest totaling 126,900 shares, an increase of 31.9% from the October 31st total of 96,200 shares. Based on an average daily trading volume, of 39,500 shares, the short-interest ratio is currently 3.2 days. Approximately 0.9% of the shares of the stock are sold short.
View National Research's Short Interest
.

When is National Research's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our NRC earnings forecast
.

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRC) released its quarterly earnings results on Tuesday, November, 7th. The company reported $0.32 EPS for the quarter. The company had revenue of $37.95 million for the quarter. National Research had a net margin of 19.33% and a trailing twelve-month return on equity of 40.74%.

How often does National Research pay dividends? What is the dividend yield for National Research?

National Research declared a quarterly dividend on Friday, November 17th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.12 per share on Friday, January 12th. This represents a $0.48 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Thursday, December 28th.
Read our dividend analysis for NRC
.

Is National Research a good dividend stock?

National Research (NASDAQ:NRC) pays an annual dividend of $0.48 per share and currently has a dividend yield of 1.16%. The dividend payout ratio is 41.38%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for NRC.

What ETF holds National Research's stock ?

Small Cap US Equity Select ETF holds 16,946 shares of NRC stock, representing 2.76% of its portfolio.

What is Michael D. Hays' approval rating as National Research's CEO?

85 employees have rated National Research Chief Executive Officer Michael D. Hays on Glassdoor.com. Michael D. Hays has an approval rating of 87% among the company's employees.

What other stocks do shareholders of National Research own?

Based on aggregate information from My MarketBeat watchlists, some companies that other National Research investors own include Altria Group (MO), Enterprise Products Partners (EPD), AbbVie (ABBV), Dominion Energy (D), Gilead Sciences (GILD), Pfizer (PFE), Toronto-Dominion Bank (TD), Verizon Communications (VZ), Wells Fargo & Company (WFC) and TD Ameritrade (AMTD).

Who are National Research's major shareholders?

National Research's stock is owned by many different retail and institutional investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (13.00%), Morgan Stanley (3.83%), Conestoga Capital Advisors LLC (3.15%), Northern Trust Corp (1.13%), Touchstone Capital Inc. (1.09%) and iA Global Asset Management Inc. (1.02%). Insiders that own company stock include Amandla Mk Trust, Joann M Martin, Jona S Raasch and Kevin R Karas.
View institutional ownership trends
.

How do I buy shares of National Research?

Shares of NRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does National Research have any subsidiaries?
The following companies are subsidiares of National Research: National Research Corporation Canada, PatientWisdom Inc., and The Governance Institute.
Read More
This page (NASDAQ:NRC) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -